Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
Kevin C MaDiya SurieAdam S LauringEmily T MartinAleda M LeisLeigh PapalambrosManjusha GaglaniChristie ColumbusRobert L GottliebShekhar GhamandeIthan D PeltanSamuel M BrownAdit A GindeNicholas M MohrKevin W GibbsDavid N HagerSafa SaeedMatthew E PrekkerMichelle Ng GongAmira MohamedNicholas J JohnsonVasisht SrinivasanJay S SteingrubAkram KhanCatherine L HoughAbhijit DuggalJennifer G WilsonNida QadirSteven Y ChangChristopher MallowJennie H KwonBijal ParikhMatthew C ExlineIvana A VaughnMayur RameshBasmah SafdarJarrod MosierEstelle S HarrisNathan I ShapiroJamie FelzerYuwei ZhuCarlos G GrijalvaNatasha HalasaJames D ChappellKelsey N WomackJillian P RhoadsAdrienne BaughmanSydney A SwanCassandra A JohnsonTodd W RiceJonathan D CaseyPaul W BlairJin H HanSascha EllingtonNathaniel M LewisNatalie ThornburgClinton R PadenLydia J AthertonWesley H SelfFatimah S DawoodJennifer DeCuirPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Updated 2023-2024 COVID-19 vaccination provided protection against both XBB and JN lineage hospitalization, but protection against the latter may be attenuated by immune escape. Clinical severity of JN lineage hospitalizations was not higher relative to XBB.